
TransMedics
Total Raised
$258.73MInvestors Count
21Deal Terms
12Funding, Valuation & Revenue
14 Fundings
TransMedics has raised $258.73M over 14 rounds.
TransMedics's latest funding round was a IPO for $91.2M on May 2, 2019.
TransMedics's latest post-money valuation is from May 2019.
Sign up for a free demo to see TransMedics's valuations in May 2019 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/2/2019 | IPO | $91.2M | 2 | |||
7/12/2016 | Growth Equity - II | $12.5M | 1 | |||
5/26/2016 | Growth Equity | $51.2M | 4 | |||
9/21/2015 | Unattributed | |||||
6/4/2015 | Series F |
Date | 5/2/2019 | 7/12/2016 | 5/26/2016 | 9/21/2015 | 6/4/2015 |
|---|---|---|---|---|---|
Round | IPO | Growth Equity - II | Growth Equity | Unattributed | Series F |
Amount | $91.2M | $12.5M | $51.2M | ||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 2 | 1 | 4 |
TransMedics Deal Terms
12 Deal Terms
TransMedics's deal structure is available for 12 funding rounds, including their IPO from May 02, 2019.
Round | IPO | Growth Equity - II | Growth Equity | Unattributed | Series F |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Growth Equity - II | |||||||||||||||
Growth Equity | |||||||||||||||
Unattributed | |||||||||||||||
Series F |
TransMedics Investors
21 Investors
TransMedics has 21 investors. Flagship Pioneering invested in TransMedics's Growth Equity - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
6/22/2000 | 7/12/2016 | 10 Series A, Series B (2004), Series B - II (2006), Series C (2007), Series D (2010), Series D - II (2011), Series E (2012), Series F (2015), Growth Equity (2016), Growth Equity - II (2016) | Venture Capital | Massachusetts | ||
6/22/2000 | 7/12/2016 | 7 Series A, Series D (2010), Series D - II (2011), Series E (2012), Series F (2015), Growth Equity (2016), Growth Equity - II (2016) | Venture Capital | California | ||
11/21/2012 | 7/12/2016 | 3 Series E, Growth Equity (2016), Growth Equity - II (2016) | David Abrams, and Travis Rhodes | Private Equity | Massachusetts | |
Corporation | Maryland | |||||
Private Equity | Florida |
First funding | 6/22/2000 | 6/22/2000 | 11/21/2012 | ||
|---|---|---|---|---|---|
Last Funding | 7/12/2016 | 7/12/2016 | 7/12/2016 | ||
Investor | |||||
Rounds | 10 Series A, Series B (2004), Series B - II (2006), Series C (2007), Series D (2010), Series D - II (2011), Series E (2012), Series F (2015), Growth Equity (2016), Growth Equity - II (2016) | 7 Series A, Series D (2010), Series D - II (2011), Series E (2012), Series F (2015), Growth Equity (2016), Growth Equity - II (2016) | 3 Series E, Growth Equity (2016), Growth Equity - II (2016) | ||
Board Seats | David Abrams, and Travis Rhodes | ||||
Type | Venture Capital | Venture Capital | Private Equity | Corporation | Private Equity |
Location | Massachusetts | California | Massachusetts | Maryland | Florida |
TransMedics Acquisitions
3 Acquisitions
TransMedics acquired 3 companies. Their latest acquisition was Summit Aviation on August 16, 2023.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
8/16/2023 | Acquired | 2 | ||||
8/2/2023 | ||||||
8/1/2023 |
Date | 8/16/2023 | 8/2/2023 | 8/1/2023 |
|---|---|---|---|
Investment Stage | |||
Companies | |||
Valuation | |||
Total Funding | |||
Note | Acquired | ||
Sources | 2 |
Compare TransMedics to Competitors

G-Level is an online retailer that sells clothing, accessories, footwear, and home decor items. The company serves a customer base that includes both men and women. It is based in Hasselt, Belgium.

C Change Biosciences specializes in surgical support technology for the medical sector, focusing on infection prevention and workflow efficiency. The company offers automated systems for producing and maintaining sterile slush, essential for organ preservation during surgeries, and provides sealed containers that protect against airborne contaminants. These products are primarily used in operating rooms and by clinical teams during complex surgical procedures. It was founded in 2004 and is based in Winston-Salem, North Carolina.
Verimetra aims to make medical instruments "smart" and manufacturers miniature thin film sensors used in medical applications that involve very small high end catheters. The Company designs and manufactures sensors using micro-electromechanical systems (MEMS) technology, which is the only method available that produces sensors small enough to be embedded in surgical devices without changing their basic form or function, allowing the company's customers to sell the same products, now "smart", without requiring the surgeon to use a new device. Verimetra aims to make medical devices "smart" by embedding (US Patent 6,494,882) a variety of small sensors at an place on or within the device. Simply stated, the company make "dumb" metal tools "smart". Examples include forceps, grippers, retractors, drills, and other surgical devices. Through the use of Verimetra's products, medical device manufacturers are able to deliver features and functionality that, depending on the medical procedure, improve outcomes, reduce risk and shorten patient recovery times. Verimetra's new product features are also used by manufacturers to strengthen their market position, enter new markets and maintain gross margins. Verimetra aims to give these manufacturers a way to accomplish these goals by adding features at a low cost without product redesign. Furthermore, in many instances, Verimetra's customers' goals will be met by the transformation of a re-usable product (one-time sale) into a smart disposable product (one sale per procedure).
CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.

Cardiola have designed a patented device, the m.pulse device designed to treat chronic heart failure (CHF), non-surgically, in a patient's home.
NeoChord focuses on beating heart mitral valve repair within the healthcare sector. The company offers the neochord artificial chordae delivery system, an echo-guided treatment for mitral valve regurgitation. It provides consultation services and resources for patients and healthcare professionals. NeoChord was formerly known as mValve. It was founded in 2007 and is based in Osseo, Minnesota.
Loading...

